330 related articles for article (PubMed ID: 25673730)
1. Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.
Hida AI; Bando K; Sugita A; Maeda T; Ueda N; Matsukage S; Nakanishi M; Kito K; Miyazaki T; Ohtsuki Y; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Aogi K; Moriya T
J Clin Pathol; 2015 May; 68(5):356-61. PubMed ID: 25673730
[TBL] [Abstract][Full Text] [Related]
2. Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells.
Hida AI; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Moriya T
Breast Cancer; 2015 Mar; 22(2):129-34. PubMed ID: 23543399
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
4. An interobserver reproducibility analysis of Ki67 visual assessment in breast cancer.
Shui R; Yu B; Bi R; Yang F; Yang W
PLoS One; 2015; 10(5):e0125131. PubMed ID: 25932921
[TBL] [Abstract][Full Text] [Related]
5. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers.
Hayashi S; Kitada M; Sato K; Matsuda Y; Ishibashi K; Oikawa K; Miyokawa N; Hirata S
Breast Cancer; 2014 Jan; 21(1):47-51. PubMed ID: 22467403
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer.
Robertson S; Stålhammar G; Darai-Ramqvist E; Rantalainen M; Tobin NP; Bergh J; Hartman J
J Clin Pathol; 2018 Sep; 71(9):787-794. PubMed ID: 29588372
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.
Tendl-Schulz KA; Rössler F; Wimmer P; Heber UM; Mittlböck M; Kozakowski N; Pinker K; Bartsch R; Dubsky P; Fitzal F; Filipits M; Eckel FC; Langthaler EM; Steger G; Gnant M; Singer CF; Helbich TH; Bago-Horvath Z
Virchows Arch; 2020 Oct; 477(4):545-555. PubMed ID: 32383007
[TBL] [Abstract][Full Text] [Related]
8. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
9. Interlaboratory variability of Ki67 staining in breast cancer.
Focke CM; Bürger H; van Diest PJ; Finsterbusch K; Gläser D; Korsching E; Decker T;
Eur J Cancer; 2017 Oct; 84():219-227. PubMed ID: 28829990
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
11. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study.
Chen Y; Klingen TA; Wik E; Aas H; Vigeland E; Liestøl K; Garred Ø; Mæhlen J; Akslen LA; Lømo J
Diagn Pathol; 2014 Dec; 9():230. PubMed ID: 25522915
[TBL] [Abstract][Full Text] [Related]
13. An interobserver reproducibility analysis of size-set semiautomatic counting for Ki67 assessment in breast cancer.
Wang YX; Wang YY; Yang CG; Bu H; Yang WT; Wang L; Xu WM; Zhao XL; Zhao WX; Li L; Song SL; Yang JL
Breast; 2020 Feb; 49():225-232. PubMed ID: 31911370
[TBL] [Abstract][Full Text] [Related]
14. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
15. [Expression of Ki67 and clinicopathological features in breast cancer].
Wang B; Wang X; Wang J; Xuan L; Wang Z; Wang X; Gao J; Zhang H
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):273-5. PubMed ID: 24989913
[TBL] [Abstract][Full Text] [Related]
16. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.
Zhong F; Bi R; Yu B; Yang F; Yang W; Shui R
PLoS One; 2016; 11(2):e0150505. PubMed ID: 26928407
[TBL] [Abstract][Full Text] [Related]
18. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups.
Aleskandarany MA; Rakha EA; Macmillan RD; Powe DG; Ellis IO; Green AR
Breast Cancer Res Treat; 2011 Jun; 127(3):591-9. PubMed ID: 20623333
[TBL] [Abstract][Full Text] [Related]
19. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.
Tang LH; Gonen M; Hedvat C; Modlin IM; Klimstra DS
Am J Surg Pathol; 2012 Dec; 36(12):1761-70. PubMed ID: 23026928
[TBL] [Abstract][Full Text] [Related]
20. Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis.
Dieci MV; Barbieri E; Bettelli S; Piacentini F; Omarini C; Ficarra G; Balduzzi S; Dominici M; Conte P; Guarneri V
J Clin Pathol; 2012 Jun; 65(6):503-6. PubMed ID: 22389512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]